Form 4: Catalyst Pharma CSO's Equity Stake Grows Post-Vesting

Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, increased her direct beneficial ownership of common stock following the vesting of restricted stock units.

Summary

• Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions related to her beneficial ownership.
• On December 29, 2025, 6,667 shares of common stock were acquired due to the vesting of restricted stock units (RSUs).
• Concurrently, 2,369 shares of common stock were disposed of to satisfy applicable withholding taxes upon the vesting of restricted common stock.
• Following these transactions, Ms. Sundaram directly beneficially owns 54,804 shares of common stock.
• Ms. Sundaram also beneficially owns 798,437 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a scheduled compensation event for a key executive, leading to an increase in their direct equity stake, which aligns executive interests with shareholders. The tax-related disposition is a routine part of such events and not indicative of negative sentiment.

Positives

• The Chief Strategy Officer's direct beneficial ownership of common stock increased by 4,298 shares (6,667 acquired 2,369 disposed) following the RSU vesting, indicating continued alignment with shareholder interests.
• The vesting of restricted stock units represents a scheduled compensation event, reflecting the company's commitment to its executive compensation plan.

Negatives

• A portion of the vested shares (2,369 shares) was withheld by the Registrant to cover applicable withholding taxes, resulting in a reduction of the total shares received by the reporting person.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The increase in the Chief Strategy Officer's direct equity ownership may be viewed positively as it signals continued commitment and alignment of interests with long-term shareholder value.
• Employees (specifically the CSO): The vesting of RSUs represents a realization of a portion of their compensation package, contributing to their personal wealth.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Chief Strategy Officer, Equity Compensation